Facebook
X
LinkedIn
ForwardPharmacy Grand Rounds
The Next Dex Thing? Corticosteroids in ARDS
- ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
- Session Type: Knowledge-based
- CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following:
- AAPA Category 1 CME Credits
- ACPE
- AMA PRA Category 1 Credits™
- ANCC
- Session Fee: Free for Mayo Clinic staff
SESSION LOCATIONS
Live Session: (11:00am - 11:45am CST)
Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.
Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date
COURSE DESCRIPTION
Acute Respiratory Distress Syndrome (ARDS) has been a difficult clinical syndrome to treat as few interventions have been shown to provide major benefits despite extensive research. One pharmacological therapy class that is frequently debated for their utility in ARDS is corticosteroids. There is significant practice variability in their use due to studies producing conflicting results over the last few decades. Recently, the DEXA-ARDS and RECOVERY trials have shown the potential benefits of corticosteroids in ARDS which could lead to practice changes. This presentation will review the pathophysiology of ARDS and corticosteroids impact, compare and contrast major historic key literature, and discuss recent landmark trials including how they fit into the landscape of what is already known.
At the conclusion of this knowledge-based CE session, participants should be able to:
- Describe the mechanism of benefit for corticosteroids in Acute Respiratory Distress Syndrome (ARDS)
- Compare and contrast key historic literature evaluating the use of corticosteroids in ARDS
- Identify how recent landmark trials on corticosteroids in ARDS impacts management
FACULTY INFORMATION
Nicholas J. Vollmer, PharmD
PGY2 Critical Care Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN
Nick received a Doctor of Pharmacy degree from Drake University in Des Moines, IA and recently completed a PGY1 at Mayo Clinic Hospital – Rochester. He is the now a PGY2 Critical Care Pharmacy Resident and has practice interests include acute care and emergency medicine.
DISCLOSURE STATEMENTS
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.
Listed below are individuals with control of the content of this program:
The faculty report the following relationships:
- Nicholas J. Vollmer PharmD
- Declares no financial relationships pertinent to this session
- Declares off-label use of devices and medications will be discussed during this presentation, including:
- Albuterol
- Atracurium
- Cisatracurium
- Dexamethasone
- Hydrocortisone
- Iloprost
- Ketoconazole
- Methylprednisolone
- Nitric oxide
Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. Members include:
- Brenda Amaris
- Mary Ellen Cordes, MS, APRN, CNC, NE-BC
- Michael Huckabee, MPAS, PA-C, PhD
- Wayne (Nick) Nicholson, MD, PharmD, BCPS
- Garrett Schramm, PharmD, BCPS
- Lee Skrupky, PharmD, BCPS